Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution
Eltrombopag received FDA approval for the treatment of refractory severe
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version
Getting personal with myelodysplastic syndromes: is now the right time?
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge
Clonal Hematopoiesis and therapy related MDS/AML
Clonal Hematopoiesis is defined as the presence of mutations in peripheral blood in the absence of myeloid malignancies and is thought to occur as a normal part of ageing due to the fitness advantage conferred by these mutations in an ageing hematopoietic compartment.
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We evaluated the efficacy and safety of the smoothened inhibitor glasdegib in HMA-failure MDS (n = 35, median age 73 years). According to the
Sarah was ready for a great career, but the diagnosis changed her plans... temporarily!
Imagine being ready to launch your career, then being thrown off course by both aplastic anemia and PNH, all at once! Listen to Sarah's story of her path to survivorship here.